Vintafolide is an investigational targeted cancer therapeutic currently under development by Endocyte and Merck & Co. It is a small molecule drug conjugate consisting of a small molecule targeting the folate receptor which is overexpressed on certain cancers such as ovarian cancer and a potent chemotherapy drug vinblastine.
thumbnail
ATC prefix
L01
ATC suffix
CA06
CAS number
742092-03-1
IUPAC name
N-(4-[(2-Amino-4-oxo-14-dihydropteridin-6-yl)methyl]aminobenzoyl)-(L)-γ-glutamyl-(L)-α-aspartyl-(L)-arginyl-(L)-α-aspartyl-(L)-α-aspartyl-(L)-cysteine disulfide with methyl (5S7R9S)-5-ethyl-9-[(3aR4R5S5aR10bR13aR)-3a-ethyl-45-dihydroxy-8-methoxy-6-methyl-5-(2-[(2-sulfanylethoxy)carbonyl]hydrazinylcarbonyl)-3a455a6111213a-octahydro-1H-indolizino[81-cd]carbazol-9-yl]-5-hydroxy-145678910-octahydro-2H-37-methanoazacycloundecino[54-b]indol-9-carboxylate
This page contains content from the copyrighted Wikipedia article "Vintafolide"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
